Anthropic buys Mithril Medicine, a one-person biotech that ran a muscular dystrophy drug programme with Claude
What's the deal? Anthropic has acquired Mithril MedicineDealroom has a profile for this one. Try Dealroom →, a Cambridge, Massachusetts biotech whose founder Cody Tranbarger was its only full-time employee. Anthropic disclosed the deal on 27 October in a post on its drug-development work; R&D World reports the acquisition closed in July. Terms were not disclosed. Mithril's programmes for two rare muscular dystrophies, LAMA2-related congenital muscular dystrophy and alpha-dystroglycanopathy, become Anthropic's first in-house drug programmes, and Tranbarger joins Anthropic to continue them and start several more.
How one person ran it: Tranbarger used Claude to organise contracts, logistics and experiments with 11 outside labs, alongside eight paid part-time consultants and advisers. Mithril designed bispecific antibodies that bridge laminin-α4 to dystroglycan to re-anchor muscle fibres, and went from idea to proof of principle in mice in under 18 months. In a pilot, seven mice given one antibody format showed about twice the grip strength and peak force of four control mice. The technical report is not peer reviewed, and R&D World notes the study was not randomised and the groups were tested months apart, so the report itself calls for blinded replication. Anthropic says a drug could be ready for human trials as soon as late 2028.
Who is behind it: Tranbarger, a Harvard MS/MBA biotech graduate who worked at Prime Medicine and Casdin Capital, was an entrepreneur-in-residence at Atlas Venture, which provided a small seed round. He was also known on X as the anonymous biotech commentator "Professor Oak" and revealed his identity with the deal. Anthropic calls the model "Pipeline-in-a-Person" and plans to test it on more rare-disease programmes.
Context: The deal came with an update on six Claude drug-development partnerships: Generate Biomedicines (a CAR-T design about 70% shorter that produced roughly 10 times more receptors in lab tests), Divergence Labs (about 35,000 antibody designs for food allergies in a month), BigHat Biosciences (about 1,010 variants tested in 10 weeks, with binding improved more than 10x), Enveda (manufacturing-document review time cut 89%), The Column Group's new company Pleiades, and Bristol Myers Squibb on clinical-trial planning. It follows Anthropic's purchase of the small biology AI startup Coefficient Bio in April.
Read more: Anthropic, Mithril technical report (PDF), R&D World, Seeking Alpha, Andrew Curran on X
Image credit: Anthropic
